Citadel Advisors
CNTB

Citadel Advisors’s Connect Biopharma Holdings CNTB Stock Holding History

Citadel Advisors’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,000
Closed -$19.3K – 14601
2024
Q4 		$19.3K Buy
+14,000
New +$16.1K ﹤0.01% 13203

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Citadel Advisors's CNTB Position: Q2 2026 in Review

Citadel Advisors sold out of Connect Biopharma Holdings (CNTB) in Q2 2026, closing a stake of 76,074 shares — an estimated $199K sold.

Citadel Advisors first reported a position in CNTB in Q1 2021 and held it in 8 quarters. The position peaked at $4.54M in Q1 2021. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Citadel Advisors reported no remaining Connect Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 76,074 Connect Biopharma Holdings shares in Q2 2026, an estimated $199K.
  • Citadel Advisors first reported a position in Connect Biopharma Holdings in Q1 2021 and held it in 8 quarters.
  • Citadel Advisors's Connect Biopharma Holdings position peaked at $4.54M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.